Computational methods have changed what can be triaged before an experiment is run. Interaction hypotheses that once needed months of biochemistry can now be generated in hours, and compound sets that would be expensive to test can be narrowed in silico first. What has not changed is that these are hypotheses: they set priorities for experiments, they do not replace them.
ICDMO covers four complementary areas — molecular simulation, AI screening, antibody and protein design, and bioinformatics — as a computational CDMO. We deliver the in silico work and the validation plan that follows from it; the laboratory work itself is run by your team or by qualified partners.
100–400 ns MD simulations for protein–protein, protein–ligand, and protein–membrane systems. RMSD, RMSF, hydrogen-bond occupancy, and MM/GBSA binding free energy analysis included.
AI-powered prediction of PPI interfaces, allosteric pockets, enzyme active sites, and protein–antibody epitopes. Confidence-ranked results with publication-quality 3D visualisation.
Complex structure prediction for protein–DNA, protein–RNA and intrinsically disordered regions, delivered with per-interface confidence and predicted contact maps.
These frameworks are open to everyone, so running them is not the differentiator. Framing the question correctly, choosing the method for a stated reason, checking consistency across methods, recognising when a run has failed, and interpreting the biology — that is the work. Deliverables are research-use, with methods and parameters documented.
Genome-wide PPI network screening to reveal novel druggable targets and functional interaction partners for your therapeutic area.
Virtual screening of multi-million compound libraries against AI-predicted binding sites — delivering ranked hits with predicted ADMET profiles.
MM/GBSA and related approaches used as relative ranking tools within an SAR cycle — useful for ordering analogues, not for quoting absolute binding free energies.
Model-guided nanobody and IgG assessment, humanisation scoring and variant ranking — from antigen sequence to a prioritised list of binders worth expressing and testing.
Multi-omics integration to generate candidate biomarker panels. Where sample size cannot support a validated classifier we say so and scope what would be needed instead.
Integrative bioinformatics analyses connecting genomic variants, expression changes, and protein function for mechanism-of-disease studies.
Note: Computational predictions prioritise hypotheses; they do not independently establish binding, biological activity, therapeutic efficacy, safety or clinical validity. Performance depends on input quality, target class, available structural evidence and the applicability domain of the chosen methods. All services are research use only and not intended for diagnostic or therapeutic purposes; turnaround times are indicative and confirmed after scoping.
Share your research question and we will recommend an approach, say what it can and cannot resolve, and follow up with a no-obligation technical proposal. Initial response within one business day.
Contact Us Online Consultation